These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 24847003)
21. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134 [TBL] [Abstract][Full Text] [Related]
22. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model. Zhu P; Sieben CJ; Xu X; Harris PC; Lin X Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903 [TBL] [Abstract][Full Text] [Related]
23. Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease. Zhang M; Srichai MB; Zhao M; Chen J; Davis LS; Wu G; Breyer MD; Hao CM Int J Med Sci; 2019; 16(1):180-188. PubMed ID: 30662341 [No Abstract] [Full Text] [Related]
24. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Lamming DW; Mihaylova MM; Katajisto P; Baar EL; Yilmaz OH; Hutchins A; Gultekin Y; Gaither R; Sabatini DM Aging Cell; 2014 Oct; 13(5):911-7. PubMed ID: 25059582 [TBL] [Abstract][Full Text] [Related]
25. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Pema M; Drusian L; Chiaravalli M; Castelli M; Yao Q; Ricciardi S; Somlo S; Qian F; Biffo S; Boletta A Nat Commun; 2016 Mar; 7():10786. PubMed ID: 26931735 [TBL] [Abstract][Full Text] [Related]
26. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). García-Martínez JM; Alessi DR Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875 [TBL] [Abstract][Full Text] [Related]
28. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair? Weimbs T Cell Cycle; 2006 Nov; 5(21):2425-9. PubMed ID: 17102641 [TBL] [Abstract][Full Text] [Related]
29. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906 [TBL] [Abstract][Full Text] [Related]
30. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines. Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233 [TBL] [Abstract][Full Text] [Related]
31. Rapamycin-encapsulated nanoparticle delivery in polycystic kidney disease mice. Yamaguchi S; Sedaka R; Kapadia C; Huang J; Hsu JS; Berryhill TF; Wilson L; Barnes S; Lovelady C; Oduk Y; Williams RM; Jaimes EA; Heller DA; Saigusa T Sci Rep; 2024 Jul; 14(1):15140. PubMed ID: 38956234 [TBL] [Abstract][Full Text] [Related]
32. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition. Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229 [TBL] [Abstract][Full Text] [Related]
34. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870 [TBL] [Abstract][Full Text] [Related]
35. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922 [TBL] [Abstract][Full Text] [Related]
36. mTORC2 is required for proliferation and survival of TSC2-null cells. Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669 [TBL] [Abstract][Full Text] [Related]
37. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562 [TBL] [Abstract][Full Text] [Related]
38. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957 [TBL] [Abstract][Full Text] [Related]
39. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Montero JC; Chen X; Ocaña A; Pandiella A Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482 [TBL] [Abstract][Full Text] [Related]
40. Rapamycin and mTORC2 inhibition synergistically reduce contraction-stimulated muscle protein synthesis. Ogasawara R; Knudsen JR; Li J; Ato S; Jensen TE J Physiol; 2020 Dec; 598(23):5453-5466. PubMed ID: 32893874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]